909
HLAVNÍ506722701005185134178232252
TÉMA533422701003981147194
Biologická46833370100435998113152191206236271306
léčba50053370100155182120155
dyslipidemií517633701003874104119134172188226261321336351
|5584227010018
211561722701006191120
14.425553085366984
Schwartz5245540833365103154187208232263
GG,8025540834489102
Steg920554083325387127
PG,1062554083358093
Szarek1170554083336295116150181
M136655408355
et14365540833457
al.1508554083324760
ODYSSEY15845540834793127159192224261
OUTCOMES18605540834792126165211266299333
Committees22085540834077135193208231255289324351
and25755540833270109
Investigators.2699554083155384119145169184425654083387091128149176189
Alirocumab62965408338546889126158195253285323
and9686540832966105
Cardiovascular1088654083376990128143180212244271302340355387407
Outcomes15116540834482104134171228263289
After1816654083385681114135
Acute19666540833870107129162
Coronary2143654083387495132170202223257
Syndrome.2415654083295997136157193251286298
N272865408341
Engl27856540832967105120
J42575408324
Med4647540835590130
2018;6097540833468100131143
379:7677540833567100113
2097–2107.8957540833569104137169201232264296302
15.425853085366883
Steg523854083325387127
PG,665854083357992
Szarek773854083326094115149179
M,9688540835367
Bhatt10508540833573106127152
DL12178540834577
et13098540833456
al.1380854083324760
Effect1455854083325170105137161
of16328540833656
Alirocumab170385408340567192129162200258290329
on20478540833776
Mortality21388540835492114138171187202224258
After2411854083405984118139
Acute25668540834071109132166
Coronary2747854083397698135425954083387091125
Syndromes.5659540833363101140162199257292319333
Circulation913954083405576107145160193214230268306
2019;12349540833569100131143
140:13939540833465101114
103–112.1522954083346699135166194224236
16.4251053085366985
Jukema5251054083256393128185218
JW,7581054083258493
Szarek8671054083336295116150181
M,106310540835569
Zijlstra1147105408339546984110134155188
LE135010540833366
et143110540833557
al.15041054083334861
ODYSSEY158010540834894128161193225262
OUTCOMES185810540834892126165211266299333
Committees220610540834178136194209232256290325352
and257310540833371110
Investigators.269910540831553851191461691844251154083387091128149176190
Alirocumab630115408338546889126159196254286325
in97011540831249
Patients10351154083326485100135173194221
With12711154083557193131
Polyvascular14171154083336985117151184210242280295327348
Disease17801154083425884118150176211
and200611540832967106
Recent212711540833367100133171192
Acute233411540833970107130163
Coronary25121154083377496133171203224257
Syndrome:278511540832959974251254083385996155190202
ODYSSEY64312540834793127159192224261
OUTCOMES91912540834792126165210265299332
Trial.1267125408332506597113125
J1408125408324
Am144712540834199
Coll15621254083397692107
Cardiol16851254083407394132147185201
2019;190112540833468100130143
74:20601254083346476
1167–1176.21521254083346193125158189216246278291
17.4251353085366876
Goodman51713540834786125164222254293
SG,8251354083368093
Aylward9341354083447490141174195233
PE,11821354083397184
Szarek12811354083366598119153184
M1480135408358
el155313540833753
al.16211354083355063
ODYSSEY170013540835096130163195227264
OUTCOMES197913540835195129168214269302336
Committees233013540834380139197212234258292328354
and270013540833573112
Investigators.2827135408318564251454083326693116131170202224261283310323
Effects7641454083375675109142166194
of97314540834261
Alirocumab1049145408346617698135167205263295335
on139914540834280
Cardiovascular14951454083447798136151189221254281313351366398419
Events193014540833769103141163190
After21361454083456489123144
Coronary229514540834582103141179211232267
Bypass257714540834072112145171198
Surgery.279014540833775964251554083387394128138
J579155408324
Am61815540834199
Coll7321554083407793108
Cardiol8561554083397293132147185201
2019;107215540833468100130143
74:12301554083356577
1177–1186.13221554083356292126159189217248283297
18.4251653085366884
Schwartz5241654083306299149181202226257
GG,7951654083418598
Steg9081654083305184123
PG,10461654083327689
Szarek11501654083305891112145175
M1340165408352
et140616540833254
al.14751654083294456
ODYSSEY154616540834490123155187219255
OUTCOMES181616540834488122160205260292326
Committees215716540833773131188203225249282317343
and251516540832967105
Investigators.263516540831250811141411631782172484251754083225880107120
Peripheral5601754083336687102141179214235268283
Artery8581754083385984117138172
Disease10451754083435884118150176211
and127117540832967106
Venous139217540833365103141179205
Thromboembolic16121754083306990127185224262297355394432448463494
Events21221754083306195133154182
After23191754083385781115136
Acute247017540833869107129163
Coronary26481754083377495132170202223257
Syndrome:42518540833262101140161199257292304
Role7451854083357389124
of88518540833756
Lipoprotein(a)9571854083314786125164186223245279294332351381399
and137118540833270109
Modification149618540835493132147165182214247269284322360
by187218540833970
Alirocumab:1957185408341577293130163201259291330342
Prespecified23151854083355690117156191224239257274308348
Analysis267818540834180112127159186201227
of42519540833757
the4971954083226095
ODYSSEY60719540834793127160192224261
OUTCOMES88419540834691125164210265298332
Randomized123119540833668106145184242257286320360
Clinical16061954083405570108123155188203
Trial.1825195408332496597112125
Circulation19661954083395576107145160192214229267306
2020;228719540833468101135148
141:24501954083356696104
1608–1617.257019540833465101136173204235265295301
19.4252053085366982
Bittner522205408336517398136171192
VA,7292054083367489
Szarek8332054083326194115149180
M,102820540835468
Aylward11112054083417187138171192230
PE135620540833568
et143920540833456
al.15112054083314759
ODYSSEY158620540834793127159192224261
OUTCOMES186220540834792126165210265299332
Committees221020540833976135193208230254288324350
and257620540833169109
Investigators.270020540831452841181451681834252154083387092129151178191
Effect6322154083335170105138162
of80921540833757
Alirocumab881215408341567192130162200258290330
on122621540833776
Lipoprotein(a)13172154083314786125164186223245279294332351381399
and173121540833270109
Cardiovascular18562154083407394132147185217250276309346362394415
Risk22862154083365178107
After24092154083416085118140
Acute256421540834172110133167
Coronary274621540834077981364252254083387091125
Syndrome.56522540833363101140162199257292304
J885225408324
Am92422540834199
Coll10382254083407793108
Cardiol11622254083407294132147185201
2020;137822540833468101135148
75:15412254083356778
133–144.16352254083346497133164195232244
20.4252353085367287
Ray5272354083336697
KK,6392354083336984
Colhoun7382354083387591129167205243
HM,99623540834297111
Szarek11222354083305992113147178
M1315235408352
et138323540833153
al.14522354083294558
ODYSSEY152523540834591125157190222259
OUTCOMES179923540834589123163208263296330
Committees214423540833875133191206229253287322349
and250823540833068107
Investigators.263023540831351821161431661822202534252454083225980107121
Effects5612454083355473107140164192
of76824540833958
alirocumab842245408333496485122155192250283322
on117924540833978
cardiovascular12722454083336687125140178210243270302340355387408
and169624540833371110
metabolic182224540835994116149188227243258290
outcomes212724540833977100131168226261288
after24302454083345378111133
acute257824540833466104126160
coronary275324540833370921294252554083387091125
syndrome5652554083286199138160197255290
in87125540831654
patients9402554083407395110145183205232
with11882554083526790128
or133125540833961
without14072554083526890129167205228
diabetes:16502554083405587126162184218244257
a1922255408334
prespecified19712554083396094121160196228243261278313352
analysis233925540833371104119151178193219
of257325540833958
the26462554083246297
ODYSSEY2758255408349951294252654083326495131
OUTCOMES57126540834488121159204258290324
randomised9092654083185088126163221235261295334
controlled125826540832864102123143180195210244283
trial.1556265408318395486100113
Lancet16842654083286198130162184
Diabetes18832654083425788127162183216243
Endocrinol214026540833067105143175195210248285300
2019;24552654083316596125138
7:260826540833140
618–628.26632654083316191127164197230242
21.4252753085367082
Ridker5222754083405695125159180
PM,71827540833993107
Revkin84027540834075107138154192
J,104827540832841
Amarenco1104275408346104136157191229261298
P1418275408339
et147327540833861
al.15492754083375265
SPIRE16292754083377287123156
Cardiovascular18012754083447798136151189221254281313351366398420
Outcome223627540835290113143180239274
Investigators.25252754083195789123150173188227259281318340367381
Cardiovascular4252854083407394132147185217250277309347362394415
Efficacy856285408337557290122155187221
and109228540833775114
Safety12212854083377089123146179
of141628540834161
Bococizumab149228540834078111148181196225263321353393
in190028540831957
High-Risk197228540834964103141163200216242272
Patients.22592854083407294109144182203231245
N2519285408349
Engl258328540833875114130
J2728285408329
Med277228540835994134
2017;42529540833468100129139
376:5802954083346698110
1527–1539.7052954083356598131163194224257290301
22.4253053085367288
Ridker5283054083355089119153175
PM,71830540833488101
Tardif8353054083325981119134153
JC,10043054083236477
Amarenco109630540834098131152186224256293
P1404305408335
et145430540833355
al.15253054083314659
SPIRE15993054083326781117151
Investigators.17653054083145283117144167183222254276313334361375
Lipid-Reduction21553054083314685101140162199234274311343368383421459
Variability26303054083346687102134174189204219242275
and42531540833270109
Antidrug-Antibody5493154083387798113152173211250272314352373388427466506538
Formation11023154083306789147179201216254292
with14103154083486386124
Bococizumab.154931540833372104141174189218256314346385397
N1962315408342
Engl201931540833168107122
J2157315408322
Med219431540835287126
2017;23363154083316597126136
376:24873154083326496108
1517–1526.26113154083326292122154185215248281295
23.4253253085367287
Cui5283254083417792
Y,63632540833543
Huo69532540834482120
Y,83032540833644
Li88932540833247
X952325408338
et100532540833557
al.10773254083324861
Tafolecimab,11533254083336180117133168201216274306345357
a1526325408332
novel157332540833776108142158
potential174632540833978100133171193208240256
long-acting20173254083155392131153185217241257295334
PCSK9236632540833576110144180
monoclonal256132540835896134173205221259297330345
antibody:4253354083327091107146185224256270
efficacy710335408337557391123156188221
and94733540833472111
safety10743354083296281115137171
in126133540831755
healthy133133540834075107123145183214
and156033540833573112
hypercholesterolemia168733540834171111147168199237275291326353376410431468484519577592624
subjects.232633540832966106121156189213240254
Eur25953354083367293
Heart270433540834782113135159
J2879335408327
2020;42534540833468101135148
doi.org/10.1093/ehjci/ehaa946.3327.588345408338779210514316520322926229430633736840443646149253054657859361865068872175378782285987290794097310061012
24.4253553085367186
Pisciotta5263554083385279111126164186210243
L,78435540833448
Favari8473554083356496129150165
E,102835540833548
Magnolo109135540835790129167205221259
L1365355408334
et141535540833658
al.14893554083344962
Characterization156635540834381113134167199223257278294323357378394432470
of205135540834059
three21263554083246283117153
kindreds22943554083324886125146181220246
with25563554083536891129
familial270035540832154112127143158190205
combined42536540833168126165181218253293
hypolipidemia73336540833565105144160175214229268303360375407
caused11563654083286199125160199
by137036540833668
loss-of-function14533654083125077103124164183203223262299331355371409447
mutations191536540835592115148169184222261287
of221736540833554
ANGPTL3.228636540833984128164198231266279
Circ25803654083375374105
Cardiovasc270036540833770911291441824253754083326591123
Genet56437540834379117152174
2012;75437540833468100129142
5:91137540833445
42–50.97237540833466101135169181
25.4253853085367287
Ahmad52738540834684142174213
Z,75638540834255
Banerjee82638540834073111146168183218253
P,109538540834044
Hamon115438540834981139178216
S1385385408337
et143838540833456
al.15093854083375265
Inhibition15893854083205896111150165188203241280
of188438540834261
Angiopoietin-Like196038540834684123138176216255270305327342380403436451481515
Protein24913854083396097119153168206
32712385408339
With276638540836279101139
a425395408332
Monoclonal47239540835593131170202218256294327342
Antibody82939540834281102117157195235267
Reduces111139540833772111149181215242
Triglycerides13683954083345167105121153184218239255293328355
in173839540831654
Hypertriglyceridemia.180839540834577117152173198220235274289321353386407423462497555570602615
Circulation24383954083425778109147162194216231269308
2019;276139540833670101132144
140:42540540833465101114
470–486.5554054083346699137174210245258
26.4254153085367187
Raal52741540833971104119
FJ,6614154083365567
Rosenson74341540833977104139177203241280
RS,10384154083397285
Reeskamp113841540833974109136166199257296
LF145041540833467
et153241540833760
al.16074154083355063
ELIPSE16854154083366883119151184
HoFH188441540834786119163
Investigators.20624154083185687121148171187225258280316338365379
Evinacumab24564154083366883121154186224281314353
for28244154083225981
Homozygous42542540834482141179207241280318356382
Familial82342540833261119134150164196212
Hypercholesterolemia.105042540834476116152173204242280296331358381415436473489524582597629642
N1708425408344
Engl176842540833270109124
J1908425408324
Med194742540835490129
2020;209142540833569102136148
383:225542540833468102114
711–720.23844254083346794127159193227240
27.4254353085367180
Rosenson5204354083347299134172198236275
RS,8104354083336780
Burgess9054354083337192131165192219
LJ,11394354083295769
Ebenbichler122343540833170105143182198230268283318339
CF157843540833770
et166343540833254
al.17334354083294558
Evinacumab18064354083316278116148181218276308348
in216943540831350
Patients22354354083336586102136175196224
with24744354083496487125
Refractory26144354083336887110143175199236257291
Hypercholesterolemia.42544540834476116151173204242280296331358381414436473489524582597629642
N1082445408345
Engl114244540833371110125
J1282445408325
Med132244540835489129
2020;146644540833468101135148
383:163044540833468102114
2307–2319.175944540833469103136168200235266296307
28.4254553085367288
Macchi52845540835587119150188203
C,74645540834053
Sirtori814455408333476893130152167
CR,9964554083407690
Corsini11014554083407798125140178193
A1310455408340
et136645540833356
al.14374554083324760
A1512455408341
new156845540833873124
dawn170745540833870121160
for18824554083185677
managing197545540835789127159198214251290
dyslipidemias:22814554083387097112127166181220255313328360387399
The269645540833271106
era28174554083345588
of42546540833757
rna-based4974654083215991114154187213248288
therapies.8004654083226095116149188204239266279
Pharmacol109446540833673105126185217249286302
Res14124654083357097
2019;152446540833468100130143
150:16824654083356599112
104413.180946540833466102139169199212
29.3047553085357184
https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-19/new-314655408335567911814415618220225330535736840242846049251255056560261465167271073575579383085188992093596198610191040106110981136115611941226124112621301132013401382141414351472148715241540157716161647166917051725175717891812182718581891191719561991200620432100213421572187221722392275230923602382
-drugs-coming-up-in-the-field-of-lipid-control.30476540832161821211601862072412773363513894284504895285515676056286506887237467657828168328718939339529739891004104310591097112011531190122912501272130913251338
30.3047753085367287
Ray3150754083356899
KK,3264754083347185
Landmesser33657540833164102141199234261287322344
U,37247540834354
Leiter3793754083316581103137158
LA39667540833174
et40567540833355
al.4127754083314659
Inclisiran420275408314528499114140155176209247
in44657540831452
Patients4532754083346688103138176198225
at47737540833153
High4841754083445998136
Cardiovascular4992754083397293131146184216249276308346361393415
Risk5422754083355076106
with3047854083516689127
Elevated3189854083334883115148170203243
LDL34478540833277110
Cholesterol.35728540834078116132167194217251272309325338
N392585408345
Engl39858540833371110125
J412585408324
Med41658540835489129
2017;43098540833468100130139
376:4464854083346698110
1430–1440.4590854083346597132170201232269305317
31.3047953085366981
Wright3143954083557591129167188
RS,3346954083336779
Collins3440954083387490105120157183
MG,36399540835195109
Stoekenbroek3763954083305187123153186224263285321357387
RM41659540833388
et42689540833153
al.4336954083304558
Effects4409954083304967102134158185
of46099540833554
Renal46789540833368106138153
Impairment48469540831270109141156177235270308329
on51909540833573
the5278954083195792
Pharmacokinetics,53859540833370102123304710540835790122159189206244279301316348376389
Efficacy,3451105408335537088120153185219229
and369510540833371111
Safety38211054083346786120143176
of401310540833958
Inclisiran:40871054083165486102116143157179212250262
An436410540834381
Analysis446010540834381114129161188203229
of470410540833958
the47781054083236196
ORION-7489010540834885101148194217248
and515310540833472111
ORION-1527910540834986101149195218248
Studies.30471154083325492131146180207221
Mayo328311540835587118156
Clin34541154083405570108
Proc35771154083355693126
2020;371811540833468101135148
95:38821154083346879
77–89.397611540833469101137172183
32.30471253085367186
Hovingh314912540834886118134172211249
GK,34131254083478397
Lepor352612540833469108147168
NE,37091254083488295
Kallend38191254083387287102137175214
D4049125408348
et411312540833759
al.41881254083355063
Inclisiran42661254083185689104119145160181214252
Durably453312540834987108141181197228
Lowers477712540833472123157178206
Low-Density499812540833572123145192228266292307330363
Lipoprotein5377125408334508912830471354083396097119153168206
Cholesterol326813540834078116132167194217251272309325
and360813540833270109
Proprotein37321354083355593132154191213247262300
Convertase404713540834077115146181202226259286321
Subtilisin/Kexin438313540833270109131146161176202217255281317351383399436
Type483513540833260100135
94985135408334
Expression503413540833365105126160187214229267305
in535413540831552
Homozygous542213540834482304714540835898126161201240279306
Familial336914540833868127143158174207222
Hypercholesterolemia:360714540835183124160182214253292309344372396430452490507542601617650662
The428514540833979115
ORION-2441614540835390106155202225257
Pilot46891454083415672111133
Study.48381454083386099139172182
Circulation50361454083466283115154170203225241280319
2020;537114540834075108143157
141:30471554083346596104
1829–1831.31661554083356699133171202233267298307
33.30471653085367186
Raal314816540833871103119
FJ,32821654083355466
Kallend33631654083387187102137175214
D,359216540834859
Ray366616540833871102
KK378316540833774
et387216540833759
al.39461654083355063
ORION-9402416540835086102150195218253
Investigators.42921654083185687121148171187225258279316338365379
Inclisiran46861654083175588103118144159180213251
for49521654083215980
the50481654083246297
Treatment51601654083355387119140198233272293
of546816540834059
Heterozygous304717540834479101135156194222256294332371397
Familial345917540833362120135150165197212
Hypercholesterolemia.368717540834476116151172203241280296330357380414435473489523581596628642
N4344175408345
Engl440417540833370110125
J4544175408324
Med458417540835489129
2020;472817540833468101135148
382:489117540833569103115
1520–1530.50211754083356598132170201231264298311
34.30471853085367388
Ray315118540834073104
KK,32701854083407691
Wright33761854083628398137175197
RS,35881854083407487
Kallend36901854083407389104138177216
D3921185408350
et398618540833961
al.40631854083365164
ORION-10414318540835188103151197220250282
and444018540833775114
ORION-11456918540835288104152197220251279
Investigators.48631854083195789123150173188227259281318340367381
Two525918540833784122
Phase539618540834077110304719540832661
33123195408336
Trials3174195408333516698114140
of332919540833858
Inclisiran34021954083165486101116142157178211249
in366619540831654
Patients37351954083366890105140178200227
with39781954083516789127
Elevated41211954083334883115148170204243
LDL438019540833278110
Cholesterol.450619540834078117133167194217251272310325338
N4860195408345
Engl492119540833371110125
J5062195408325
Med510219540835691130
2020;524819540833569102136149
382:541219540833569103116
1507–1519.30472054083346498131163194224255285296
35.30472153085367186
GrahamMJ,31482154083426396134167224292318330
Lee34932154083296399
RG,36072154083337791
Brandt37132154083335588126165187
TA391621540833067
et399821540833254
al.40672154083304558
Cardiovascular41402154083387192130145183215248275307345360392413
and456921540832967106
Metabolic469121540835287109142181220236251283
Effects49892154083304968103135159187
of519121540833555
ANGPTL3526121540833984128164198231267
Antisense304722540834179101116142177215241276
Oligonucleotides.33392254083476378117155193231263278313352374389428463490503
N3858225408344
Engl391822540833270109124
J4058225408324
Med409722540835590129
2017;424222540833468100129139
377:439622540833466101111
222–232.452222540833469104138170204237250
36.30472353085367288
Tirronen3150235408331486990128166201239
A,340523540833852
Hokkanen347323540834280111142176214249287
K,377523540833347
Vuorio383823540833370108130145183
T,403723540833039
Ylä-Herttuala40912354083334982104150185206231255293325341373
S.447923540833144
Recent453823540833368101135173194
advances474823540832968101134172204238265
in502823540831250
novel509423540833573105140155
therapies52652354083195792113146186201236263
for30472454083185678
lipid3140245408315306984123
disorders.32792454083385379117139177212233260274
Hum356824540834482140
Mol372324540835593109
Genet384724540834479117152175
2019;403724540833468100130143
28:41952454083356881
R49–R54.429124540833570104141178214249262
37.30472553085367180
Zwol314225540834393131147
WV,3304255408363103112
Rimbert343125540834157115154190211236
A,368225540834761
Kuivenhoven37582554083417893126161199237276308342381
JA.41542554083307085
The425425540833877113
Future43822554083387497135156191
of458825540834362
Lipid-lowering46662554083365291107146168185223275309331346385424
Therapy.510525540833878113134168207238249
J5369255408329
Clin54142554083456075114
Med304726540835490129
2019;319126540833569100131143
8:335026540833446
1085.341226540833465101135147
38.30472753085367288
Witztum31502754083577395126151189246
JL,34122754083235569
Gaudet349627540834375113152187209
D,372027540834555
Freedman37912754083315185120160218250288
SD409427540833277
et418627540833355
al.42572754083304659
Volanesorsen43312754083357186119157192219257278306341379
and472527540833169108
Triglyceride48482754083324964103119150182216237252291326
Levels51892754083316597131147173
in537727540831452
Familial54442754083316130472854083577288103135150
Chylomicronemia321228540834078109125163221236268289327365400458473505
Syndrome.373328540833262101140161198256291304
N4052285408345
Engl411228540833270109125
J4252285408324
Med429128540835590129
2019;443628540833468100130143
381:459428540833469101109
531–542.47182854083356899131165200233246
39.30472953085367185
Gouni-Berthold314729540834281119157172194231267288312351389405444
I,360629540831326
Alexander36472954083395590121154192231266287
V,394929540833443
Digenio40072954083445998133171186224
A4246295408340
et430129540833456
al.43732954083294558
Apolipoprotein444629540833979117133148187226266287325346380395433
C-III489529540833851688398
inhibition50092954083125088103143158181196234272
with52972954083486486125
volanesorsen54372954083306730473054083154785120147185207234269307
in337030540832057
patients34433054083447798114148187208236
with36943054083567194132
hypertriglyceridemia384130540834374114149171195217232271287318350384405421459494552567599
(COMPASS):445630540832363108163199237271303322334
a4805305408337
randomized,48583054083205391130169227242271305345358
double-blind,52313054083438212015917521023327330473154083153068107119
placebo-controlled31823154083385486119152192230254287324363384406443459474509548
trial.3746315408321435890106119
Atheroscler388031540834162100135157194221253268303324
Suppl421931540833370109149165
2017;439931540833468100130139
28:45543154083346880
e1–e2.46493154083346497133168180
40.30473253085367489
Gelrud31513254083478398119157196
A,336332540834458
Digenio343632540834964103138176191229
A,368032540834459
Alexander37543254083445994126158196236270292
V4061325408339
et411532540833456
al.41873254083355063
Treatment42653254083365387119141199234272293
with45743254083536991130
volanesorsen47193254083357288120158193220258280307342380
(VLN)51153254083216093138157
reduced52873254083245898135167201241
triglycerides3047335408322435998114146177211233249288323350
and341233540833876115
pancreatitis354333540834477115148169203235257273295311337
in389633540832058
patients39693354083447799115150188210238
with42223354083567295133
FCS437133540833778112
and449833540833876115
sHTG462933540833176110153
vs479833540833764
placebo:48773354083446093125159199238250
results51433354083266087125140163191
of534933540834362
the542733540832665100
APPROACH304734540834177111147194234273318
and338034540833270109
COMPASS.350434540834085140176214248280293
J3813345408324
Clin38523454083405570108
Lipidol39753454083324786102141179195
2018;418534540833468100131143
12:43443454083346476
537.443534540833568100106
41.30473553085366982
https://ir.ionispharma.com/news-releases/news-release-details/akcea-and-ionis-report-top-line-results-broaden-study-waylivrar.314435540834365901301571691962172332552652813203583744004394785115325916246386707077667928298649169439659871021103710721104113111671194122012571292134413711392141414491465150015321559159416181658169417161749176517801806183218631894192519591991201420472085212521472163220222412256228223042326236030473654083397799124143166203242266282297335370393415449476513528551579600640661698731770805843866893916954993102510471099113111621178119312261248128113021312
42.30473753085366984
Alexander31443754083455993123154191229262282
VJ,34403754083406070
Xia35243754083425687
S,362537540833647
Hurh368637540834884104141
E3841375408337
et389237540833858
al.39643754083365062
N-acetyl404037540834869100131164185217232
galactosamine-conjugated42863754083427387117148171207232264321334371405426459494532545582619650671703741
antisense50413754083367393107131165202227261
drug53163754083426198136
to546637540832561
APOC3mRNA,304738540834174120159193259293337376389
triglycerides3449385408318385188102132161193213226263296321
and378438540832764101
atherogenic38983854083284884117137172209242279292322
lipoprotein4233385408311256299136156191211243257293
levels.45393854083114474107120145156
Eur47093854083286382
Heart480538540834073103122145
J4964385408320
2019;49973854083306292121132
40:51423854083306476
2785–2796.52313854083306193125159189220251285296
43.30473953085367185
Tsimikas31473954083385973131145175208234
S,339539540833850
Viney34593954083415794129160
NJ,36333954083507486
Hughes373439540834886124162196223
SG397139540833781
et406739540833960
al.41423954083365164
Antisense422039540834684105119145180217243278
therapy45123954083276499119152191222
targeting47483954083265979117151173188225264
apolipoprotein(a):502739540833675113129143182220259280317338372386424442472489501
a3047405408331
randomised,30934054083195188125162219233258292330342
double-blind,344940540833471108146161194216255270284320358370
placebo-controlled38334054083355081112144182220242274310347367388424438452486524
phase437240540833572103128162
14548405408331
study.45934054083234581119150159
Lancet47664054083286097128160181
2015;49624054083306394122132
386:51084054083316498110
1472–1483.52324054083316091124157187217251284296
44.30474153085367490
Viney31524154083415895130162
NJ,33294154083507587
van343241540833669107
Capelleveen355541540834578117152168183218250285320358
JC,39294154083297083
Geary402741540834984116137172
RS421441540834074
et430341540834062
al.43804154083375265
Antisense446141540834684106121147182220246282
oligonucleotides47584154083425873112150189226258274309347369385424458485
targeting52594154083265980119154176191229268
apolipoprotein(a)304742540833271111127142181220260282320342376391429449479497
in356042540832058
people363442540834479118158175210
with38594254083567295133
raised40084254083265974100136176
lipoprotein(a):41994254083203575114154176213235269285323342373391403
two461842540832680118
randomised,47524254083255997136175234249275311351363
double-blind,513142540834382120160176211234275291306344384396
placebo-controlled,30474354083395587119153192231254288325363385406443459474509549561
dose-ranging362443540833876103138161183216254293308346385
trials.4024435408322435991106132146
Lancet418543540833265103135169191
2016;439143540833569101132144
388:455043540833469104117
2239–2253.468243540833469104137174206241275308321
45.30474453085367186
Tsimikas31484454083305267124139169203229
S,339244540833043
Karwatowska-Prokopczuk34504454083326687140173194231282309339372394431451488519556596628659697727
E,419244540833043
Gouni-Berthold425044540834180118156171193230265286310348386402441
I4706445408312
et473444540833456
al.48054454083294457
AKCEA-APO(a)-LRx487844540833873112145187209250285333352382400422455491524
Study54174454083305189304745540833870
Investigators.31324554083135182116143166181220253274311333360374
Lipoprotein(a)35214554083294483122162183221242276291329348379396
Reduction393345540833368107145177201216254293
in424145540831250
Persons43064554083336788115153192218
with45394554083496487125
Cardiovascular46794554083387092130145183215248274306344359392413
Disease.51074554083435985120151178213225
N5347455408343
Engl540545540833068107122
J3047465408324
Med308646540835590130
2020;323146540833468101135148
382:339446540833469102115
244–255.352446540833466103141172207239251
Získejte283811301765690137196256288333393
také6998113017642103163222
nové9448113017663125181240
aktuální12078113017658117162228289322388421
informace1651811301762895136198240339400447508
a21828113017657
kredity2262811301765798159223256301358
v26438113017654
rámci27208113017639100199245278
celoživotního30218113017643104136199249281338399444510543609672
vzdělávání37168113017653104168229261323378438504536
➜432581160216134
https://online.solen.cz4482811301761161612062713183523924334955625946276937547868338969289891056108911361187
Rádi26259210423164309462539
vám85759210423138283519
pomáháme14315921042315730654268884699112261371
v285759210423138
on-line305159210423151309398475550709852
vzdělávání395959210423138262415559636782913105812161292
2388364670435153307
on-line4376885017060124161192223288346
kurzů8056885017058121162212275
a11036885017059
kongresů11846885017058117181243284342388451
7200232172300435153307460613
účastníků23917647017063109170215259323354412474
160239864670435153307460
přednášek23736885017063104162224289348393452509
134073272300435153307460613
vydaných5417647017055114174234298351394458
certikátů10227647017045104145191222290348409451514